Equillium (LTS:0A4D) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0A4D Equillium Inc LTS:0A4D
31 GF Score
Price $2.61
GF Value $0.10
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Equillium Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

LTS:0A4D
31GF Score
Equillium Inc LTS:0A4D
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Equillium (LTS:0A4D) Overvalued in 2026?

Based on GuruFocus' analysis, Equillium stock appears to be overvalued. The current stock price of $2.61 is trading 2510% above its estimated GF Value™ of $0.10. GuruFocus considers Equillium to be Significantly Overvalued.

Key valuation signals for LTS:0A4D:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $0.10 vs. price of $2.61 (2510% above fair value)
  • GF Score™: 31/100 with 2 warning signs

No single metric tells the full story. See the LTS:0A4D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Equillium Business Description

Other Exchanges EQ:USA0FY:Germany
Address 2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
31GF Score

Get the complete analysis for LTS:0A4D

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.61
Price
$0.10
GF Value